1. CMU Intellectual Repository

Browsing by Author Sumitra Thongprasert

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 18 to 34 of 34 < previous 
Issue DateTitleAuthor(s)
1-May-2013Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysisChee Khoon Lee; Chris Brown; Richard J. Gralla; Vera Hirsh; Sumitra Thongprasert; Chun Ming Tsai; Eng Huat Tan; James Chung Man Ho; Da Tong Chu; Adel Zaatar; Jemela Anne Osorio Sanchez; Vu Van Vu; Joseph Siu Kie Au; Akira Inoue; Siow Ming Lee; Val Gebski; James Chih Hsin Yang
1-Jun-2011An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East AsiaJohn Wen Cheng Chang; Sumitra Thongprasert; Elaine Wright; Kenneth Tsang; Heung Tae Kim; Myung Ju Ahn; Joo Hang Kim; Jin Hyoung Kang; Sang We Kim; Stefan Walzer
1-Sep-2005Lung cancer in Maharaj Nakorn Chiang Mai Hospital: Comparison of the clinical manifestations between the young and old age groupsAthavudh Deesomchok; Namporn Dechayonbancha; Sumitra Thongprasert
1-Sep-2010Lung cancer working group reportNagahiro Saijo; Masahiro Fukuoka; Sumitra Thongprasert; Yukito Ichinose; Tetsuya Mitsudomi; Tony Shu Kam Mok; Yuichiro Ohe; Keunchil Park; Yi Long Wu
1-Oct-2007Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.Chaiyut Charoentum; Sumitra Thongprasert; Busayamas Chewasakulyong
1-Nov-2007Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancerChaiyut Charoentum; Sumitra Thongprasert; Busayamas Chewasakulyong; Juntima Euathrongchit; Sirikul Sorraritchingchai; Sutthirak Munprakan
1-Feb-2006A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancerSumitra Thongprasert; Sirikul Soorraritchingchai; Busayamas Chewaskulyong; Chaiyut Charoentum; Sutthirak Munprakan
1-Jan-2012A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational studyJun Ho Yi; Sumitra Thongprasert; Jeeyun Lee; D. C. Doval; Se Hoon Park; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim
27-May-2014Prevalence and relationship between major depressive disorder and lung cancer: A cross-sectional studyBenchalak Maneeton; Narong Maneeton; Jirayu Reungyos; Suthi Intaprasert; Samornsri Leelarphat; Sumitra Thongprasert
1-Jan-2014A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)Yuankai Shi; Joseph Siu Kie Au; Sumitra Thongprasert; Sankar Srinivasan; Chun Ming Tsai; Mai Trong Khoa; Karin Heeroma; Yohji Itoh; Gerardo Cornelio; Pan Chyr Yang
1-Oct-2013Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from AsiaShukui Qin; Yuxian Bai; Ho Yeong Lim; Sumitra Thongprasert; Yee Chao; Jia Fan; Tsai Shen Yang; Vajarabhongsa Bhudhisawasdi; Won Ki Kang; Yu Zhou; Jee Hyun Lee; Yan Sun
1-Jan-2016Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn Lii Cheng; Sumitra Thongprasert; Ho Yeong Lim; Wattana Sukeepaisarnjaroen; Tsai Shen Yang; Cheng Chung Wu; Yee Chao; Stephen L. Chan; Masatoshi Kudo; Masafumi Ikeda; Yoon Koo Kang; Hongming Pan; Kazushi Numata; Guohong Han; Binaifer Balsara; Yong Zhang; Ana Marie Rodriguez; Yi Zhang; Yongyu Wang; Ronnie T.P. Poon
1-Dec-2005Reliability of the Thai-Modified Function Living Index Cancer questionnaire version 2 (T-FLIC 2) for the evaluation of quality of life in non-small cell lung cancer patientsSumitra Thongprasert; Sukanya Intarapak; Prissana Saengsawang; Kanittha Thaikla
26-Sep-2015Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 StudyJohan F. Vansteenkiste; Jean Luc Canon; Filippo De Braud; Francesco Grossi; Tommaso De Pas; Jhanelle E. Gray; Wu Chou Su; Enriqueta Felip; Hiroshige Yoshioka; Cesare Gridelli; Grace K. Dy; Sumitra Thongprasert; Martin Reck; Paola Aimone; Gena Atalla Vidam; Pantelia Roussou; Ying A. Wang; Emmanuelle Di Tomaso; Jean Charles Soria
10-Jun-2012Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trialGiorgio V. Scagliotti; Maciej Krzakowski; Aleksandra Szczesna; Janos Strausz; Anatoly Makhson; Martin Reck; Rafal F. Wierzbicki; Istvan Albert; Michael Thomas; Jose Elias Abrao Miziara; Zsolt S. Papai; Nina Karaseva; Sumitra Thongprasert; Elsa Dalmau Portulas; Joachim Von Pawel; Ke Zhang; Paulina Selaru; Lesley Tye; Richard C. Chao; Ramaswamy Govindan
1-Aug-2016Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancerTony Mok; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Chong Jen Yu; Sumitra Thongprasert; Jennifer Sandoval-Tan; Jin Soo Lee; Fatima Fuerte; David S. Shames; Barbara Klughammer; Matt Truman; Pablo Perez-Moreno; Yi Long Wu
1-Aug-2013Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS studyYi Long Wu; Masahiro Fukuoka; Tony S.K. Mok; Nagahiro Saijo; Sumitra Thongprasert; James C.H. Yang; Da Tong Chu; Jin Ji Yang; Yuri Rukazenkov
Showing results 18 to 34 of 34 < previous